As of 2024-07-27, the Relative Valuation of Bristol-Myers Squibb Co (BMY) is (9.72) USD. This relative valuation is based on P/E multiples. With the latest stock price at 50.45 USD, the upside of Bristol-Myers Squibb Co based on Relative Valuation is -119.3%.
The range of the Relative Valuation is (80.43) - 88.47 USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 26.5x - 32.6x | 30.7x |
| Forward P/E multiples | 19.4x - 24.7x | 20.6x |
| Fair Price | (80.43) - 88.47 | (9.72) |
| Upside | -259.4% - 75.4% | -119.3% |
| Date | P/E |
| 2024-07-26 | -16.63 |
| 2024-07-25 | -14.93 |
| 2024-07-24 | -14.73 |
| 2024-07-23 | -14.17 |
| 2024-07-22 | -14.07 |
| 2024-07-19 | -14.06 |
| 2024-07-18 | -13.98 |
| 2024-07-17 | -14.23 |
| 2024-07-16 | -13.58 |
| 2024-07-15 | -13.24 |
| 2024-07-12 | -13.34 |
| 2024-07-11 | -13.44 |
| 2024-07-10 | -13.56 |
| 2024-07-09 | -13.47 |
| 2024-07-08 | -13.19 |
| 2024-07-05 | -13.08 |
| 2024-07-03 | -13.21 |
| 2024-07-02 | -13.34 |
| 2024-07-01 | -13.62 |
| 2024-06-28 | -13.69 |
| 2024-06-27 | -13.69 |
| 2024-06-26 | -14.01 |
| 2024-06-25 | -13.91 |
| 2024-06-24 | -13.92 |
| 2024-06-21 | -13.83 |
| 2024-06-20 | -13.53 |
| 2024-06-18 | -13.46 |
| 2024-06-17 | -13.51 |
| 2024-06-14 | -13.58 |
| 2024-06-13 | -13.68 |
| 2024-06-12 | -13.98 |
| 2024-06-11 | -14.18 |
| 2024-06-10 | -14.04 |
| 2024-06-07 | -13.68 |
| 2024-06-06 | -13.48 |
| 2024-06-05 | -13.60 |
| 2024-06-04 | -13.77 |
| 2024-06-03 | -13.77 |
| 2024-05-31 | -13.55 |
| 2024-05-30 | -13.27 |
| 2024-05-29 | -13.27 |
| 2024-05-28 | -13.35 |
| 2024-05-24 | -13.60 |
| 2024-05-23 | -13.70 |
| 2024-05-22 | -13.96 |
| 2024-05-21 | -13.94 |
| 2024-05-20 | -14.30 |
| 2024-05-17 | -14.52 |
| 2024-05-16 | -14.54 |
| 2024-05-15 | -14.69 |